Abstract: The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R) (+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(−)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

Abstract: Composition and methods of using melanin, or melanin-promoting compounds, for inhibiting angiogenesis to treat angiogenesis-dependent diseases, such as macular degeneration and cancer.

Abstract: Composition and methods of using melanin, or melanin-promoting compounds, for inhibiting angiogenesis to treat angiogenesis-dependent diseases, such as macular degeneration and cancer.

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.

Abstract: A method of inhibiting angiogenesis in a female mammal to regulate fertility comprising administering to the female mammal an effective amount of an angiogenesis inhibiting compound. In addition, a method of inhibiting angiogenesis in a female mammal to treat a disease or condition of the reproductive tissue that is mediated by angiogenesis comprising administering to the female mammal an effective amount of an angiogenesis inhibiting compound. AGM-1470 is provided as such an angiogenesis inhibiting compound.

Abstract: Composition and methods of using melanin, or melanin-promoting compounds, for inhibiting angiogenesis to treat angiogenesis-dependent diseases, such as macular degeneration and cancer.

Abstract: A method of inhibiting angiogenesis in a female mammal to regulate fertility comprising administering to the female mammal an effective amount of an angiogenesis inhibiting compound. In addition, a method of inhibiting angiogenesis in a female mammal to treat a disease or condition of the reproductive tissue that is mediated by angiogenesis comprising administering to the female mammal an effective amount of an angiogenesis inhibiting compound. AGM-1470 is provided as such an angiogenesis inhibiting compound.

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.

Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: 1

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.

Abstract: The present invention relates to inhibition of angiogenesis and the treatment of diseases mediated by angiogenesis. Particularly, the invention relates to the inhibition of neovascularization and the treatment of cancer. The invention further relates to the use of cytochalasin derivatives for the inhibition of angiogenesis and the treatment of angiogenesis associated diseases.

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprise the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.

Abstract: A method of inhibiting angiogenesis in a female mammal to regulate fertility comprising administering to the female mammal an effective amount of an angiogenesis inhibiting compound. In addition, a method of inhibiting angiogenesis in a female mammal to treat a disease or condition of the reproductive tissue that is mediated by angiogenesis comprising administering to the female mammal an effective amount of an angiogenesis inhibiting compound. AGM-1470 is provided as such an angiogenesis inhibiting compound.

Abstract: The present invention relates to inhibition of angiogenesis and the treatment of diseases mediated by angiogenesis. Particularly, the invention relates to the inhibition of neovascularization and the treatment of cancer. The invention further relates to the use of cytochalasin derivatives for the inhibition of angiogenesis and the treatment of angiogenesis associated diseases. The invention also relates to new isoindolinone compounds, compositions containing them, and methods of inhibiting angiogenesis and treating angiogenesis associated diseases with the isoindolinone derivatives.

Abstract: The application discloses methods of treating mammalian diseases characterized by undesirable angiogenesis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.

Abstract: The apparatus and method comprise means to evaluate the interocular latency difference known to exist in individuals afflicted with multiple sclerosis. The apparatus includes two horizontal rows of 10 light emitting diodes separated by a horizontal partition. The upper row of diodes is seen by the eye and a lower row of diodes is seen by the other eye. Although the two rows are separated vertically, they are made to overlap optically and appear as one row by means of two periscopic eye pieces. The ten diodes in each field of view are energized (strobed) sequentially for 1/10 of the time required to scan a horizontal row. The directions of scanning in the two rows are opposite to each other. A separate diffraction line ruling is placed in each optical path to produce elongated diffraction images of each energized diode in one row which are at 45 degrees to the horizontal and at right angles to the elongated diodes in the other row.